top of page
Symbiotic Therapy
How our technology works:
Our results so far...
Preliminary fish data showed that a single subcutaneous administration of symbiotic particles delivering different therapeutic agents achieved:
-
sustained plasma levels
-
delivery of the therapeutic agents to multiple organs
-
an early safety signal characterized by reduced IL-1β (a pro-inflammatory cytokine)
-
no observed acute adverse events.
A 40-day SPRIND-funded follow-up study injecting subcutaneously symbiotic particles delivering Follistatin as therapeutic agent in aged mice showed:
-
that living microalgae remained localized at the injection site without detectable proliferation
-
that Follistatin was confirmed in target muscle and skin tissues,
-
no observed local or systemic inflammatory or immune response
-
good local tolerability throughout the study
Therapeutic agent signal in tissue
Cell staining
What do you think about our technology?
We would value your feedback. Answer a few quick questions to help us better understand how our platform is perceived and where it could create the most value.
bottom of page